Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
BCANN ASD28
- Development stage
- Phase 3
- Lead developer
- Bazelet Nehushtan
- Modality
- Metabolically Activated Prodrugs → Prodrugs/Conditional Activator Small Molecules → Small Molecules, Classical Binding Small Molecules → Small Molecules
- Administration
- Sublingual
01
Overview
BCANN ASD28 is a terpene-enriched, high-cannabidiol (CBD) and very low-tetrahydrocannabinol (THC) medical cannabis oil developed by Bazelet Nehushtan. It is specifically formulated for the treatment of autism spectrum disorder (ASD) and associated behavioral problems in children and adults. The formulation is designed to leverage cannabinoid-terpene interactions (the entourage effect) to enhance therapeutic efficacy and safety. BCANN ASD28 is administered sublingually and is currently being evaluated in a Phase 2 randomized, double-blind, placebo-controlled clinical trial in Israel.
- Brand names
- ASD 28 OilASD28 OilASD-28 OilBCANN ASD28Bcann ASD 28 OilBcann ASD28 IndicaBcann ASD28 SativaBcann Sativa Oil ASD28
- Other names
- cannabidiol + tetrahydrocannabinol + terpenesterpene-enriched CBD-dominant oilterpene-enriched high-CBD cannabis oil
02
Targets
CNR1 (Cannabinoid receptor 1)
Beyond the preview
Go deeper on BCANN ASD28.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on BCANN ASD28.